Tempest Therapeutics (NASDAQ:TPST) Stock Lifted to Hold by Wall Street Zen

Wall Street Zen upgraded shares of Tempest Therapeutics (NASDAQ:TPST) from a sell rating to a hold rating in a research report sent to investors on Saturday morning,Wall Street Zen reports.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Tempest Therapeutics in a research report on Friday, October 9th. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Reduce”.

Tempest Therapeutics Stock Down 2.2%

Shares of NASDAQ:TPST opened at $0.51 on Friday. The company has a market cap of $8.63 million, a P/E ratio of -0.12 and a beta of -1.73. Tempest Therapeutics has a 52 week low of $0.50 and a 52 week high of $11.13. The company has a 50-day moving average price of $0.87 and a 200 day moving average price of $1.22.

Tempest Therapeutics (NASDAQ:TPST) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.04). Analysts expect that Tempest Therapeutics will post -0.83 EPS for the current year.

Hedge Funds Weigh In On Tempest Therapeutics

A hedge fund recently bought a new stake in Tempest Therapeutics stock. Squarepoint Ops LLC purchased a new stake in Tempest Therapeutics, Inc. (NASDAQ:TPST) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 30,900 shares of the company’s stock, valued at approximately $34,000. Squarepoint Ops LLC owned approximately 0.19% of Tempest Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 22.52% of the company’s stock.

Tempest Therapeutics Company Profile

Tempest Therapeutics, Inc is a clinical-stage biotechnology company focused on developing small-molecule medicines for cancer. The company’s research combines tumor-targeted immune activation with approaches designed to disrupt tumor metabolism, with the goal of stimulating the immune system within the tumor microenvironment while limiting effects on healthy tissue.

Tempest’s pipeline has included TPST-1120, an oral, selective antagonist of peroxisome proliferator-activated receptor alpha (PPARα).